The FDA has approved Arena Pharmaceuticals’ Lorcaserin obesity drug. Having traversed an arduous course of clinical trials, regulatory review, rejection, more trials and ultimately approval, Lorcaserin (to be marketed under the name BELVIQ) now represents a significant opportunity for obesity drugs, which represent a large, untapped solution to global obesity.
The FDA has specifically approved Lorcaserin, according to Arena, “…as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index (BMI) of 30 kg/m2 or greater (obese), or 27 kg/m2 or greater (overweight) in the presence of at least one weight related comorbid condition (e.g., hypertension, dyslipidemia, type 2 diabetes).” Lorcaserin targets obesity by decreasing food consumption and promoting satiety by selectively activating serotonin 2C receptors in the brain.
MedMarket Diligence has evaluated the global market for obesity drugs and devices in the comprehensive report, “Products, Technologies and Markets Worldwide for the Clinical Management of Obesity, 2011-2019.” (Report #S835.) Below is illustrated the impact, over the next few years, on the global obesity drug market.
Source: Report #S835.